The best available first-line therapy for advanced liver cancer reaches a median survival of nineteen months.1

Around 5% of tumors carry FGF19 amplification, a subtype that does worse and recurs sooner.2

This is a cancer with a precise molecular definition and no therapy matched to it. We are closing that gap.

Please note: Zephira Genomics operates in a stealth capacity.

Everything sent here is read by someone working on it. Nothing you send is used for anything but a reply. Privacy policy.